On April 13th, Zhejiang Province officially released the first national special guidance on patent layout in the field of biopharmaceuticals, filling the gap in the systematic
This issue’s information covers GPCR biased ligand design, 3D printed biomimetic gas tubes, magnetic resonance panoramic quantitative imaging, novel mechanisms of liver transplant rejection, endogenous analgesic
On May 7, the China National Intellectual Property Administration officially released the white paper “Status of China’s Intellectual Property Protection in 2025”, comprehensively reviewed the achievements
In this issue, eight major achievements of national medicine were selected, and eight core scientific research breakthroughs were disassembled, including neuroblastoma, KRAS mutant solid tumor, fundus
On May 6th, the National Medical Products Administration (NMPA) officially approved the world’s first CDK2/4/6 inhibitor, Coumoxili Capsules (Saitanxin), independently developed by China’s biopharmaceutical subsidiary, Zhengda
This week, there are various hot topics in the financing of the medical and health field. Ganewei Medical’s multi hundred million yuan C-round enhanced tumor ablation
· Guangxi Holds Expert Review Meeting on Patent Regulations Revision · Lex Machina Releases 2026 Class Action Litigation Report · BMW's US Patent Dispute in Germany
Current biopharmaceutical financing updates: Nuanxin Jia has completed a strategic financing of 300 million yuan, leading the field of visual brain computer interfaces; Intelligent Diagnosis Technology’s
· Fujian Releases 2025 Provincial Intellectual Property Protection Typical Cases · Germany's Court Rules: AI-Generated Designs Not Protected by Copyright · USPTO Releases New Procedure for
At present, the wave of innovation in the medical and health field continues to surge, and cutting-edge technologies continue to inject new vitality into clinical diagnosis
